A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Neratinib|DRUG: T-DM1
Sponsor: NSABP Foundation Inc
Collaborators: Puma Biotechnology, Inc.